Person
Richard Vosser
1 episodes · 7 quoted claims
Richard Vosser says Novo Nordisk's coverage for its obesity drug is now around 50 million, covering most commercially insured U.S. patients.
“So their coverage is now somewhere in the region of 50 million. So they've got the bulk patients in the US.”
Making Sense (J.P. Morgan) · 0:09:58
Richard Vosser says diabetes drug prices have been falling by about 10% a year and expects obesity drug prices to follow.
“the idea that diabetes prices have been coming down by 10 % a year”
Making Sense (J.P. Morgan) · 0:10:29
Novo Nordisk spent five or six years building the obesity market with an earlier drug that produced only about 5% weight loss, according to Richard Vosser.
“And they hadn't got very far because the drug that they were using only made people lose 5 % of the body weight.”
Making Sense (J.P. Morgan) · 0:12:26
Richard Vosser says the next generation of Novo Nordisk and Eli Lilly drugs should deliver 25 to 30% weight loss, versus about 15% from catch-up rivals.
“Novo and Lily's next generation products are going to be delivering 25, 30 % weight loss in that sort of category.”
Making Sense (J.P. Morgan) · 0:15:25
Richard Vosser says GLP-1 drugs have been on the market for 10 to 15 years with no safety issues beyond tolerability.
“we've got lots and lots of years of safety data. We've talked about this for 10 years or so, 15 years these products have been on the market.”
Making Sense (J.P. Morgan) · 0:17:37
Richard Vosser says about 20% of patients do not tolerate these drugs, while 75% in the SELECT trial stayed on the drug for three to four years.
“About 20 % of patients don't tolerate these drugs. But the vast majority we've seen in the data from the SLECT trial, 75 % of patients stayed on the drug for about three to four years.”
Making Sense (J.P. Morgan) · 0:20:44
Richard Vosser says there are around 32 million diabetics in the U.S. and a similar number in Europe.
“You've got around 32 million diabetics US, same in Europe or so.”
Making Sense (J.P. Morgan) · 0:21:09